• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality
Conclusions: In absolute terms, the risk reductions mean 19 fewer CHD deaths and 7 fewer stroke deaths per 1,000 women using any HT for at least 10 years.
Source: Menopause - August 28, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”
Publication date: Available online 19 August 2015 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Frank Z. Stanczyk, Bhagu R. Bhavnani Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. This review examines critically the safety o...
Source: The Journal of Steroid Biochemistry and Molecular Biology - August 21, 2015 Category: Biochemistry Source Type: research

Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records
Conclusion: Our findings provide recent data on the types of menopausal symptoms experienced by mid-life women prescribed HT. Electronic medical records may be a rich source of data for future studies of menopausal symptoms in this population.
Source: BMC Women's Health - August 13, 2015 Category: OBGYN Authors: Matthew SussmanJeffrey TrocioCraig BestSebastian MirkinAndrew BushmakinRobert YoodMark FriedmanJoseph MenzinMichael Louie Source Type: research

Dietary isoflavones, urinary isoflavonoids, and risk of ischemic stroke in women.
CONCLUSIONS: A habitually high intake of soy isoflavones may be associated with a modest but significant increase in risk of ischemic stroke in women. However, no association was shown for the urinary excretion of isoflavonoids. PMID: 26245809 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - August 5, 2015 Category: Nutrition Authors: Yu D, Shu XO, Li H, Yang G, Cai Q, Xiang YB, Ji BT, Franke AA, Gao YT, Zheng W, Zhang X Tags: Am J Clin Nutr Source Type: research

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Hormone Therapy Increases Stroke and Venous Thromboembolism Risks in Postmenopausal Women.
According to this study. PMID: 26018007 [PubMed - as supplied by publisher]
Source: The American Journal of Nursing - May 29, 2015 Category: Nursing Authors: Carter D Tags: Am J Nurs Source Type: research

Hormone Therapy Increases Stroke and Venous Thromboembolism Risks in Postmenopausal Women
According to this study: * Hormone therapy in women who have reached menopause confers little protection against cardiovascular disease, but it significantly increases the risk of stroke and venous thromboembolic events. * A subgroup analysis showed some cardiovascular benefit when treatment was started less than 10 years after the onset of menopause.
Source: AJN - May 29, 2015 Category: Nursing Tags: Journal Watch Source Type: research

Long-term menopausal hormone therapy and health consequences - how to choose sides?
Abstract There is no debate any more on the good safety profile of postmenopausal hormone therapy (HT) in healthy perimenopausal and early postmenopausal women, but there are still many open issues related to the consequences of long-term HT, especially in older women. A recent Cochrane meta-analysis showed that women who started HT less than 10 years after the menopause had lower mortality and coronary heart disease (CHD), but more venous thromboembolism (DVT). However, in those who started treatment more than 10 years after the menopause, there was high-quality evidence that it had little effect on death or CHD ...
Source: Climacteric - May 11, 2015 Category: Geriatrics Authors: Pines A, Shapiro S Tags: Climacteric Source Type: research

Associations between postmenopausal hormone therapy and strokes in a National cohort study
The Women Health Initiative randomized clinical studies on effects of two postmenopausal hormone therapies (HT) were stopped prematurely mainly due to stroke risk.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Ellen Løkkegaard, Anne K. Nielsen, Øjvind Lidegaard Tags: O28 Source Type: research

The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women's Health Initiative: A cohort study
Stroke is the third most common cause of death and the most common cause of prolonged disability in women worldwide[1]. Therefore, the American Heart and Stroke Association recently published strict new guidelines for the prevention of stroke in women [2]. These guidelines acknowledge a number of female gender-related risk factors for stroke, such as migraine, pregnancy, pre-eclampsia, atrial fibrillation, obesity, metabolic syndrome, living alone -status and consequent delay in thrombolysis, and longevity.
Source: Maturitas - April 13, 2015 Category: Primary Care Authors: Pauliina Tuomikoski, Heli Lyytinen, Pasi Korhonen, Fabian Hoti, Pia Vattulainen, Mika Gissler, Olavi Ylikorkala, Tomi S. Mikkola Source Type: research

Bioidentical hormones, menopausal women, and the lure of the “natural” in U.S. anti-aging medicine
Publication date: May 2015 Source:Social Science & Medicine, Volume 132 Author(s): Jennifer R. Fishman , Michael A. Flatt , Richard A. Settersten Jr. In 2002, the Women's Health Initiative, a large-scale study of the safety of hormone replacement therapy (HRT) for women conducted in the United States, released results suggesting that use of postmenopausal HRT increased women's risks of stroke and breast cancer. In the years that followed, as rates of HRT prescription fell, another hormonal therapy rose in its wake: bioidentical hormone replacement therapy (BHRT). Anti-aging clinicians, the primary prescribers of ...
Source: Social Science and Medicine - March 19, 2015 Category: Psychiatry & Psychology Source Type: research

HRT review finds increased risk of blood clots and stroke
Conclusion This updated Cochrane review has found that oral HRT increases risk of stroke and blood clots, and does not appear to reduce overall risk of cardiovascular disease or death during follow-up. More exploratory analyses suggested that HRT might reduce risk of death from heart disease or non-fatal heart attack if it was started within 10 years of menopause, but this finding needs further confirmation. The review was carried out using robust methods and the trials were of good quality. Its findings are in line with the previous version of the review, and also with other reviews. There are some points to note: Thi...
Source: NHS News Feed - March 10, 2015 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Hormone therapy for preventing cardiovascular disease in post-menopausal women.
CONCLUSIONS: Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events. PMID: 25754617 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 10, 2015 Category: Journals (General) Authors: Boardman HM, Hartley L, Eisinga A, Main C, Roqué I Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B Tags: Cochrane Database Syst Rev Source Type: research

Menopausal hormone therapy and ovarian cancer: putting risk into perspective
The wide use of menopausal hormone therapy (MHT) rapidly declined a decade ago after the results of the Women's Health Initiative (WHI) showed that women treated with conjugated equine estrogens plus medroxyprogesterone acetate had an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism [1]. Increased ovarian cancer risk was not reported in the randomized WHI intervention trial nor in the extended poststopping phases of the study [2].
Source: Maturitas - February 26, 2015 Category: Primary Care Authors: Faustino R. Pérez-López, Margaret Rees Source Type: research

Menopause-related hot flashes and night sweats can last for years
According to conventional medical wisdom, menopause-related hot flashes fade away after six to 24 months. Not so, says a new study of women going through menopause. Hot flashes last, on average, for about seven years and may go on for 11 years or more. The hormonal roller coaster that comes with the end of a woman’s childbearing years can trigger a range of symptoms. Up to 80% of women going through menopause experience hot flashes. Hot flashes, also known as vasomotor symptoms, are often described as a sudden sensation of heat in the chest, face, and head followed by flushing, perspiration, and sometimes chills. Whe...
Source: New Harvard Health Information - February 23, 2015 Category: Consumer Health News Authors: Nancy Ferrari Tags: Menopause Women's Health hot flashes night sweats Source Type: news

Pages: 1  2  3  4  5  6  7  8  9